Valuation: PTC Therapeutics, Inc.

Market Cap 6.91B 6.04B 5.54B 5.17B 9.8B 658B 9.97B 66.76B 25.87B 323B 25.95B 25.38B 1,112B P/E 2026 *
94x
P/E 2027 * 33.4x
Enterprise Value 5.13B 4.48B 4.11B 3.84B 7.27B 488B 7.4B 49.53B 19.19B 239B 19.25B 18.83B 825B EV / Sales 2026 *
4.37x
EV / Sales 2027 * 3.86x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
1 day+2.41%
1 week-1.42%
Current month+2.13%
1 month+22.10%
3 months+22.93%
6 months+8.56%
Current year+9.68%
1 week 80.21
Extreme 80.21
84.37
1 month 69.46
Extreme 69.455
87.03
Current year 61.43
Extreme 61.43
87.03
1 year 43.18
Extreme 43.175
87.5
3 years 17.53
Extreme 17.53
87.5
5 years 17.53
Extreme 17.53
87.5
10 years 4.03
Extreme 4.03
87.5
Manager TitleAgeSince
Chief Executive Officer 54 2023-03-21
Director of Finance/CFO 41 2023-07-12
Chief Tech/Sci/R&D Officer - 2017-09-30
Director TitleAgeSince
Chairman 74 2004-10-31
Chairman 80 1998-03-30
Director/Board Member 65 2005-11-30
Date Insider Type Main position Quantity % Market Cap.
06-25Fiscal year

Chief Technology Officer

24,390 0.0294%
06-24Fiscal year

Chief Technology Officer

62,880 0.0758%
06-21Fiscal year

Chief Technology Officer

71,247 0.0859%
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%-1.42%+69.50%+104.84% 6.75B
+1.86%+7.65%+55.77%+158.84% 1,063B
+3.57%+7.42%+69.09%+58.92% 611B
+3.99%+7.37%+36.87%+93.77% 444B
-1.20%-1.94%+26.41%+20.22% 324B
+4.94%+4.51%+39.76%+28.93% 285B
+2.42%+1.60%+30.06%+42.24% 283B
+2.47%+6.56%-24.26%-39.60% 219B
+3.55%+6.05%+26.04%+68.52% 195B
+4.21%+6.00%+17.72%+70.33% 156B
Average +2.35%+2.18%+34.70%+60.70% 358.74B
Weighted average by Cap. +1.85%+4.14%+41.62%+80.73%

Financials

2026 *2027 *
Net sales 1.17B 1.03B 941M 878M 1.66B 112B 1.69B 11.34B 4.39B 54.79B 4.41B 4.31B 189B 1.31B 1.15B 1.05B 982M 1.86B 125B 1.89B 12.68B 4.91B 61.28B 4.93B 4.82B 211B
Net income 65.46M 57.2M 52.52M 48.98M 92.85M 6.23B 94.42M 632M 245M 3.06B 246M 240M 10.53B 178M 155M 143M 133M 252M 16.93B 257M 1.72B 666M 8.31B 668M 653M 28.62B
Net Debt -1.78B -1.56B -1.43B -1.33B -2.53B -170B -2.57B -17.23B -6.68B -83.29B -6.7B -6.55B -287B -1.84B -1.61B -1.48B -1.38B -2.61B -175B -2.65B -17.78B -6.89B -85.93B -6.91B -6.76B -296B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
26-07-02 US$83.31 +2.41% 6,777,719
26-07-01 US$81.35 -0.27% 1,221,573
26-06-30 US$81.57 0.00% 2,375,631
26-06-29 US$81.57 -3.39% 4,294,986
26-06-26 US$84.43 -0.09% 3,903,105
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
83.31USD
Average target price
93.93USD
Spread / Average Target
+12.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock